Every year, cancer claims the lives of more than half a million Americans and is the second leading cause of death in the United States. While checkpoint inhibitors and other novel immunotherapies have resulted in increased life expectancy for some people, current immunotherapies still fail in nearly 80% of cancer patients.
At Inimmune, we are using our expertise in innate immunity to produce new therapeutics that make existing immunotherapy effective for more patients.
Inimmune’s novel immunomodulating molecules are capable of reducing tumor size and slowing tumorigenesis in several pre-clinical cancer models. Nanoparticle drug delivery platforms increased the efficacy of our molecules, demonstrating both monotherapy efficacy and synergy with FDA approved combination treatments.
Our current lead IO therapeutic is INI-4001, a potent TLR7/8 agonist that has been optimized for nanoparticle delivery. INI-4001 demonstrates efficacy as monotherapy and in combination with immune checkpoint therapy (ICT) in multiple pre-clinical murine cancer models. Mechanistically, INI-4001 increases the number of APCs and enhances CD8 T cell responses in the tumor microenvironment. Clinical Phase 1 studies with INI-4001 in solid tumor cancer indications are slated to start early 2023.
In our pre-clinical pipeline, we are exploring novel compounds targeting other innate immune receptors, such as STING and CLRs, as well as advanced delivery systems to target immunotherapy directly to the tumor and tumor microenvironment.
TLR-7/8 (INI-4001), TLR-4 (INI-2002), CTLR (UM-1098), STING
Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Professional doctor or nurse giving flu or COVID-19 injection to patient. Woman in medical face mask getting antiviral vaccine at hospital or health center during vaccination and immunization campaign.